
Yan Xu
@imyanxu
@uOttawaMed #thrombosis physician | @uoftPGME & @queensu alum | career goal: improving health service delivery & outcomes
ID: 2828053053
https://www.ohri.ca/profile/yanxu 13-10-2014 19:10:10
1,1K Tweet
682 Followers
932 Following

TXA treats heavy menstrual bleeding and postpartum hemorrhage, but widespread adoption faces barriers like sexism, period poverty, and stigma. Addressing these issues could save lives & improve quality of life. Heather VanderMeulen Grace Tang Michelle Sholzberg Read: rpthjournal.org/article/S2475-…



The ISTH is pleased to recognize Marc Carrier and Alisa Wolberg as the winners of its inaugural Outstanding Mentor Awards 🥳Join us in congratulating these fantastic mentors!


Farewell to our wonderful uOttawa | Faculté de médecine, Faculty of Medicine 2024 AFC Adult Thrombosis Medicine Fellows. Great group of early career thrombosis specialists ready to take over the world :) Thank you for all your hard work and all the best in your new endeavours! Divya Karsanji Abdulmajeed Alrasheed Abdul Al-Mujalli



Arterial thrombosis (ATE) is often neglected in patients with cancer. Elegant review by Dr. Miriam Kimpton and Yan Xu reviewing the epidemiology of ATE in cancer, along with its prevention and treatment strategies. Cancers MDPI doi.org/10.3390/cancer…


Thank you Ontario Health OLMP, thank you Dynacare, thank you LifeLabs, thank you AlphaLabs, thank you University of Toronto, thank you to all members of ‘Raise the Bar’. This is a big step forward for Ontario and for 🇨🇦 Canada in promoting health equity for ppl with iron deficiency. 💥





Thanks Mathilde Gaudreau-Simard for being a guest on our most recent CSIM episode on planetary health! We're so excited to release Part 2 next week. Medicine Pods CSIM Choosing Wisely Canada Billy Silverstein Owen Luo



Rivaroxaban for 18 Months Superior to 6 Months To Prevent Recurrent VTE Events in Cancer Patients with Acute-low PE: ONCO PR Written by Joseph Kim! Summary, analysis and more AHA coverage below! cardiologynownews.org/rivaroxaban-fo… C. Michael Gibson MD




Join us today at 11am ET for the next edition of our National Thrombosis Seminar series as we discuss "The NLRP3 Inflammasome and Interleukin-1 in Thromboinflammation and #VTE" Featuring: Nicola Potere Register: buff.ly/4g04UHl #Thrombosis #Research


🩸 Meta-analysis presented at #ISTH2025 and simultaneously published in EHJ Editor-in-Chief found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.

